Efficacy and Safety of Early Switching to Dolutegravir/Lamivudine (DTG/3TC) From INSTI-based Three-drug Regimens in HIV-1-infected Adults Previously naïve Who Achieve Virological Suppression
Latest Information Update: 05 Apr 2024
At a glance
- Drugs Dolutegravir/lamivudine (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms EDOLAS
- 05 Apr 2024 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified July 2021).
- 16 Jul 2021 Planned End Date changed from 7 Feb 2022 to 1 Apr 2024.
- 13 Jul 2021 New trial record